Oral semaglutide (Rybelsus) uses a special absorption enhancer called SNAC to deliver a GLP-1 peptide drug through the stomach, offering blood sugar control, weight loss, and cardiovascular protection without injections.
First oral GLP-1Oral semaglutide is the first GLP-1 receptor agonist delivered as a pill, using SNAC technology to survive stomach acid
What the researchers found
This review covers oral semaglutide (Rybelsus), the first GLP-1 receptor agonist available as a pill rather than an injection. The drug combines semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that helps the peptide cross the stomach lining intact.
Beyond blood sugar control, the review highlights that GLP-1 receptor agonists deliver significant weight loss with low hypoglycemia risk, reduce major adverse cardiovascular events, and may protect the kidneys in patients with type 2 diabetes and chronic kidney disease. Clinical trials have shown GLP-1 RA treatment is safe and tolerated in patients with impaired renal function.
Why it matters
Peptide drugs traditionally require injection because stomach acid destroys them. Oral semaglutide solved this with SNAC technology, making GLP-1 therapy more accessible to patients who resist daily or weekly injections. This matters because adherence is a major barrier in diabetes management, and an oral option could help more patients benefit from the cardiovascular and kidney-protective effects of GLP-1 drugs.
The numbers in context
Oral formulation uses SNAC absorption enhancer · GLP-1 RAs reduce major adverse cardiovascular events · Safe in patients with CKD · Lower hypoglycemia risk than many diabetes drugs
How the study worked
Narrative review summarizing the pharmacology of oral semaglutide, the SNAC absorption technology, and clinical evidence from large trials (primarily cardiovascular outcome trials) on the efficacy and safety of GLP-1 receptor agonists in type 2 diabetes.
Who was studied
Adults with type 2 diabetes mellitus, including those with chronic kidney disease
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. It does not present new clinical data. The review focuses primarily on oral semaglutide's advantages without deeply comparing it to injectable formulations or newer dual/triple agonists that were in development at the time.
How to read the evidence
This is a narrative review summarizing published clinical trial data. The underlying evidence from cardiovascular outcome trials is strong, but this paper itself is a secondary summary rather than original research.
When this study was published
Published in 2023. Oral semaglutide remains the primary oral GLP-1 option on the market, though newer formulations and higher doses are in development, making this review still relevant.
The bigger picture
Oral semaglutide represents a landmark in peptide drug delivery — proving that absorption enhancers can make injectable peptides orally bioavailable. This technology has implications far beyond diabetes: if SNAC or similar enhancers work for other peptides, the entire peptide drug landscape could shift toward oral formulations, dramatically expanding patient access and adherence.
Questions still open
- How does the efficacy of oral semaglutide compare to the injectable version at equivalent doses?
- Could SNAC-type absorption technology be applied to other therapeutic peptides beyond GLP-1 agonists?
- What are the long-term renal outcomes for patients with CKD using oral semaglutide specifically?
Common questions
How does oral semaglutide survive stomach acid?
Is oral semaglutide as effective as the injectable version?
Read the original research
A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.
Diabetes, metabolic syndrome and obesity : targets and therapy, 16, 1709-1720
Citation
Selvarajan, Raja; Subramanian, Rashmi. (2023). A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.. Diabetes, metabolic syndrome and obesity : targets and therapy, 16, 1709-1720. https://doi.org/10.2147/DMSO.S385196